Form 4: Scott Biller Acquires Foghorn Therapeutics Stock Options

Director Scott Biller of Foghorn Therapeutics Inc. was granted stock options for 28,000 shares.

Summary

• Scott Biller, a Director at Foghorn Therapeutics Inc. (FHTX), has been granted stock options.
• The options are for 28,000 shares of common stock.
• The exercise price for these options is $4.08 per share.
• The earliest transaction date associated with this filing is June 24, 2026.
• The options vest in full on the first anniversary of the grant date, contingent on continued service as a director.
• A power of attorney was filed by Scott Biller, authorizing Michael LaCascia, Adrian Gottschalk, and Samantha Macina to execute SEC filings on his behalf.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a routine event for executive compensation and incentive alignment.

Positives

• Grant of stock options to a director, indicating potential alignment of management interests with shareholder value.
• The option grant suggests confidence in the company's future prospects by providing an incentive for continued service and performance.

Risks

• The vesting of options is contingent on continued service, meaning a departure from the board would forfeit unvested options.
• The value of the options is subject to the future performance of Foghorn Therapeutics' stock price.

Future Outlook

The filing indicates a future transaction date of June 24, 2026, for the stock options, and the options vest on the first anniversary of the grant date, subject to continued service.

Management Comments

• "The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors."
• "I hereby constitute and appoint Michael LaCascia, Adrian Gottschalk and Samantha Macina, and each of them individually, with full power of substitution, as the undersigned's true and lawful attorney-in-fact..." (from the Power of Attorney document).

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company performance and shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The stock option grant aligns director incentives with company performance, potentially benefiting shareholders if the stock price increases.
• Employees: While not directly impacting employees, such grants are part of a broader compensation strategy that can influence overall company morale and retention.
• Management: The grant provides a financial incentive for continued service and dedication to the company's success.

Next Steps

• Scott Biller's stock options will vest on the first anniversary of the grant date, provided he continues to serve on the board of directors.
• The attorneys-in-fact appointed by Scott Biller will continue to manage his SEC filings as required.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, SEC Filing, Beneficial Ownership, Grant Date, Vesting